Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

NCT00736229 on ClinicalTrials.gov · last registry update 2014-11-20

Finished June 2011, after enrolling 40 people. Primary outcome, as filed: Median Glucose Values From Steady State Through 48 Hours or Until Discharge. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Saint Luke's Health System
Sponsor type: Other
Enrollment: 40
Started: 2008-08
Primary completion: 2011-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Median Glucose Values From Steady State Through 48 Hours or Until Discharge.

Conditions studied

Hyperglycemia · Acute Coronary Syndromes · Myocardial Infarction

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.